Hiroshi Mizushima — Founder & Member of the Board

Hiroshi received his doctorate in Pharmaceutical Sciences from the University of Tokyo in 1988. During his career at the National Cancer Center, Tokyo Medical and Dental University and the National Institute of Public Health, he has focused on healthcare IT, computational biology, genomics, and rare disease R&D challenges in Japan.

In the early 2010’s, Hiroshi and Norikazu founded the Tokyo Rare Disease Forum, now with about 300 members among government officials, researchers, patient organizations, and healthcare companies.

Norikazu Eiki — Founder & Member of the Board

Nori served as President and Chairman Representative Director of Bayer Yakuhin from 2002 to 2014. After retirement, he relocated to New Jersey, USA, affiliated with the New York Consulting ABPS Group, continuing to advise Japanese government organisations and companies on policy and R&D issues.

Together with Hiroshi Mizushima, Nori has played an active role in building and managing the Tokyo Rare Disease Forum.

Photo coming soon

Rob Koremans — Founder & Member of the Board

Rob qualified as a medical doctor from RSM Erasmus University in the Netherlands with over 30 years’ experience in senior executive roles at J&J, Serono, Grünenthal, Sanofi-Aventis and Teva.

From December 2021, he has been CEO of Recordati S.p.A., focusing on building the company’s R&D activities and global market presence in rare diseases. Recordati was founded in 1926 and is recognized as a global leader in rare and ultra rare diseases.

Christian Elze — Founder & Member of the Board

Since the mid-90’s, Christian has worked as a management consultant for biopharmaceutical companies, most recently as founder and senior partner of Catenion. He has deep experience evaluating technology platforms and R&D assets across modalities and stages.

He has regularly done business in Japan for twenty years and has supported translational medicine strategies with universities including Tel Aviv University, Charité and Stanford.

Hiroshi Kowaki — CEO & Representative Director

Hiroshi is a biopharmaceutical leader with more than 25 years of experience building and scaling Japan businesses in rare disease and specialty care. After Boehringer Ingelheim and Astra Zeneca, he set up Japan subsidiaries for Alnylam and Amylyx.

He has deep expertise in Japan market entry (PMDA, MAH/ODD), NDA/BLA strategy, NHI pricing and access, and cross-functional governance with global stakeholders.